Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted...

Area of Science:

• Veterinary Medicine
• Oncology
• Biomaterials Science

Background:

• Canine brain tumors, particularly gliomas, are a significant clinical challenge with limited treatment options.
• Systemic chemotherapy for brain tumors faces limitations due to drug delivery and toxicity.
• Temozolomide is a chemotherapy agent with potential efficacy against gliomas in both dogs and humans.

Purpose of the Study:

• To evaluate the feasibility and tolerability of entotherapy, an image-guided drug-eluting microcylinder platform, for treating canine gliomas.
• To assess the safety and preliminary outcomes of implanting temozolomide-conjugated microcylinders into partially resected canine gliomas.

Main Methods:

• Four client-owned dogs with gliomas underwent craniotomy for the implantation of biopolymer microcylinders.
• Microcylinders were conjugated with temozolomide and gadolinium for image guidance and drug delivery.
• Dogs had gliomas including glioblastoma multiforme (n=1) and oligodendroglioma (n=3).

Main Results:

• All dogs recovered well from the craniotomy and microcylinder implantation procedure.
• The novel entotherapy procedure was found to be feasible and well-tolerated in tumor-bearing dogs.
• No significant neurological deficits were noted post-procedure.

Conclusions:

• Entotherapy represents a potentially viable new approach for localized chemotherapy delivery in canine brain tumors.
• The feasibility and tolerability demonstrated warrant further investigation in controlled clinical studies.
• This image-guided drug-eluting microcylinder platform may offer an alternative to systemic chemotherapy for canine gliomas.